A serum proteomic study of two case-control cohorts identifies novel biomarkers for bipolar disorder
If a GLP-1 is the right tool: how we do medical weight loss differently When we do recommend a GLP-1 medication, we offer the major options used in medical weight loss today semaglutide and tirzepatide sourced through licensed pharmacies and prescribed under physician supervision
The point is that a triple agonist needs careful evaluation before broad use
Medullary Thyroid Carcinoma (MTC) and MEN2 MTC is rare, creating two realities: If a causal effect were large, it might be detectable in very large datasetsbut evidence has not established such a signal If a causal effect were small, enormous follow-up and careful subtype adjudication would be required Because the boxed warning is MTC/MEN2-specific, a conservative clinical approach is appropriate: Avoid GLP-1 RAs in patients with personal or family history of MTC Avoid GLP-1 RAs in MEN2 The Evidence by Subtype: For common thyroid cancers, the best evidence doesn't show causation
The risk becomes more significant during the 1-3 year treatment period, especially with medullary thyroid carcinomas.1.33 events per 10,000 person-years Doctors need to evaluate this data based on each patients risk profile
